An Audience With in 2010

Filter By:

Article Type
Year

  • Francis Collins, Director of the US National Institutes of Health, discusses how translational medicine can help bolster the drug pipeline.

    An Audience With

  • The European Medicine Agency's outgoing Executive Director Thomas Lönngren discusses his 10 years on the job, the importance of regulatory science and the challenges that lie ahead for his successor.

    An Audience With

  • The Senior Vice President of Medicines Discovery and Development at GlaxoSmithKline discusses the rationale for the recent evolution of the company's research and development strategy.

    An Audience With

  • The Head of Global Scientific Strategy at Merck Research laboratories discusses research and development priorities at Merck following their merger with Schering–Plough.

    An Audience With

  • The new President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation discusses how his experience of leading Wyeth Vaccines will help the organization to reach its goal.

    An Audience With

  • The Head of Roche Pharma Research and Early Development discusses the R&D structure at Roche since the acquisition of Genentech.

    An Audience With

  • The Chairman of Biocon Limited — India's largest biotechnology company — discusses how the country could move from being a service provider to being a source of novel therapies in the future.

    An Audience With

  • The Head of the Clinical Trials Unit at the Paul Ehrlich Institute in Germany discusses the progress of a 'one stop shop' to assess applications for multinational clinical trials in Europe.

    An Audience With

  • The first executive dean for research at Harvard Medical School discusses the aims and challenges of his newly created position.

    An Audience With

  • The Executive Director of US think tankFasterCuresdiscusses how the organization acts as a catalyst to accelerate the development of innovative therapies.

    An Audience With

  • A pioneer of evidence-based medicine discusses how mathematical models can be used to understand the likely cost and health-care outcomes of therapies.

    • Bethan Hughes
    An Audience With

  • The Chairman and former Chief Executive Officer of Novartis discusses the company's approach to R&D.

    • Bethan Hughes
    An Audience With

  • The Executive Vice President of R&D at Sanofi–Aventis discusses the company's R&D strategy.

    • Bethan Hughes
    An Audience With